Comparative Adverse Effect Profiles of Platinum Drugs (original) (raw)

• Pratt WB, Ruddon RW. The anticancer drugs. New York: Oxford University Press, 1979: 12–9
  Google Scholar
• Abrams MJ, Murrer BA. Metal compounds in therapy and diagnosis. Science 1993; 261: 725–30
  PubMed CAS Google Scholar
• Lissauer. Falle Von Leucaemie. Berl Klin Wochenschr 1865; 40: 403
  Google Scholar
• Raven RW. The theory and practice of oncology: historical evolution and present principles. Carnforth: Parthenon Publishing Group, 1990: 243–56
  Google Scholar
• Albert A. Selective toxicity: the physicochemical basis of therapy. 6th ed. London: Chapman and Hall, 1979: 180–236
  Google Scholar
• Andrews PLR, Davis CJ, Bingham S, et al. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990; 68: 325–45
  PubMed CAS Google Scholar
• Fowler BA, Mistry P, Goering PL. Mechanisms of metal-induced nephrotoxicity. In: Bach PH, Lock EA, editors. Nephrotoxicity in the experimental and clinical situation. Part 2. Dordrecht: Martinus Nijhoff, 1987: 659–81
  Google Scholar
• McAlpine D, Araki S. Minamata disease an unusual neurological disorder caused by contaminated fish. Lancet 1958; ii: 629–31
  Google Scholar
• Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698
  PubMed CAS Google Scholar
• Rosenberg B, Van Camp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agent. Nature 1969; 222: 385
  PubMed CAS Google Scholar
• Horwich A. Current controversies in the management of testicular cancer. Eur J Cancer 1991; 27: 322–6
  PubMed CAS Google Scholar
• McKeage MJ, Kelland LR. New platinum drugs. In: Neidle S, Waring M, editors. Molecular aspects of anticancer drug-DNA interactions. 2nd ed. Basingstoke: MacMillian Press, 1993: 169–212
  Google Scholar
• Harrap KR. Platinum analogues: criteria for selection. In: Muggia FM, editor. Cancer chemotherapy. Massachusetts: Martinus Nijhoff, 1983: 171–217
  Google Scholar
• Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of the in vitro binding of radioactive cis- and _trans_-dichloro-diammineplatinum(II) to DNA. Chem Biol Interact 1980; 30: 151–69
  PubMed CAS Google Scholar
• Borch RF. The platinum anti-tumour drugs. In: Powis G, Prough RA, eds. Metabolism and action of anti-cancer drugs. London: Taylor and Francis, 1987: 163–93
  Google Scholar
• Sherman SE, Lippard SJ. Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 1987; 87: 1153–81
  CAS Google Scholar
• Cheung YW, Cradock JC, Vishnuvajjala BR, et al. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hos Pharm 1987; 44: 124–30
  CAS Google Scholar
• Hayes DM, Cvitkovic E, Golbey RB, et al. High dose m-platinum diammine dichloro amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372–81
  PubMed CAS Google Scholar
• Harrap KR, Jones M, Wilkinson CR, et al. Antitumour, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Cisplatin. New York: Academic Press Inc, 1980: 193–212
  Google Scholar
• Siddik ZD, Newell DR, Boxall FE, et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987; 36: 1925–32
  PubMed CAS Google Scholar
• Knox RJ, Friedlos F, Lydall DA, et al. Mechanisms of cytotoxicity of antitumour platinum drugs: evidence that _cis_-diamminedichloro and _cis_-diammine-(1,1-cyclobutano)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986; 46: 1972–9
  PubMed CAS Google Scholar
• Gore ME, Fryatt I, Wiltshaw E, et al. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989; 60: 767–9
  PubMed CAS Google Scholar
• Rossof AH, Slayton RE, Perlia CP. Preliminary experience with _cis_-diamminedichloroplatinum(II) (NSC 119875,CACP). Cancer 1972; 30: 1451–6
  PubMed CAS Google Scholar
• Bitran JD, Desser RK, Billings AA, et al. Acute nephrotoxicity following _cis_-dichlorodiammine-platinum. Cancer 1982; 49: 1784–8
  PubMed CAS Google Scholar
• Dentino M, Luft FC, Yum MN, et al. Long term effect of _cis-_diamminedichloroplatinum (CDDP) on renal function and structure in man. Cancer 1978; 41: 1274–81
  PubMed CAS Google Scholar
• Daugaard G, Abildgaard U. Renal morbidity of chemotherapy. In: Plowman PN, McElwain TJ, Meadows AJ, editors. Complications of cancer management. Oxford: Butterworth-Heinemann, 1991: 213–31
  Google Scholar
• Jones BR, Bhalla RB, Mladek J, et al. Comparison of methods of evaluating nephrotoxicity of _cis_-platinum. Clin Pharm Ther 1980; 27: 557–62
  CAS Google Scholar
• Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesaemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 1982; 66: 1767–9
  PubMed CAS Google Scholar
• Bell DR, Woods RL, Levi JA. _Cis_-diamminedichloroplatinum-induced hypomagnesaemia and renal magnesium wasting. Eur J Cancer Clin Oncol 1985; 21: 287–90
  PubMed CAS Google Scholar
• Hamilton CR, Bliss JM, Horwich A. The late effects of _cis_-platinum on renal function. Eur J Cancer Clin Oncol 1989; 25: 185–9
  PubMed CAS Google Scholar
• Bissett D, Kunkeler L, Zwanenberg L, et al. Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 1990; 62: 655–9
  PubMed CAS Google Scholar
• Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1989; 25: 1–9
  PubMed CAS Google Scholar
• Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. The renal pathology in clinical trials of _cis_-platinum (II) diamminedichloride. Cancer 1977; 39: 1362–71
  Google Scholar
• Weiner MW, Jacobs C. Mechanism of cisplatin nephrotoxicity. Fed Proc 1983; 42: 2974–8
  PubMed CAS Google Scholar
• Reece PA, Stafford I, Russell J, et al. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 1986; 4: 1392–8
  PubMed CAS Google Scholar
• Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5: 304–9
  PubMed CAS Google Scholar
• Safirstein R, Winston J, Goldstein M, et al. Cisplatin nephrotoxicity. Am J Kidney Dis 1986; 8: 356–76
  PubMed CAS Google Scholar
• Siddik ZH, Jones MR, Boxall FE, et al. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 1988; 21: 19–24
  PubMed CAS Google Scholar
• Daley-Yates PT, McBrien DCH. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 1984; 33: 3063–70
  PubMed CAS Google Scholar
• Uozumi J, Litterst Cl. The effect of cisplatin on renal ATPase activity in vivo and in vitro. Cancer Chemother Pharmacol 1985; 15: 93–6
  PubMed CAS Google Scholar
• Daley-Yates PT, McBrien DCH. The inhibition of renal ATPase by cisplatin and some bio-transformation products. Chem Biol Interact 1982; 40: 325–34
  PubMed CAS Google Scholar
• Reed E, Litterst CL, Thill CC, et al. _Cis_-diamminedichloro-platinum(II)-DNA adduct formation in renal, gonadal, and tumour tissues of male and female rats. Cancer Res 1987; 47: 718–22
  PubMed CAS Google Scholar
• Hannemann J, Duwe J, Baumann K. Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds. Cancer Chemother Pharmacol 1991; 28: 427–33
  PubMed CAS Google Scholar
• Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of _cis_-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39: 1357–61
  PubMed CAS Google Scholar
• Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 1982; 66: 31–5
  PubMed CAS Google Scholar
• Daley-Yates PT, McBrien DCH. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem Pharmacol 1985; 34: 2363–9
  PubMed CAS Google Scholar
• Desimone PA, Yancey RS, Coupai JJ, et al. Effect of forced diuresis on the distribution and excretion via urine and bile of 195platinum _cis_-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979; 63: 951–60
  PubMed CAS Google Scholar
• Comis RL. Cisplatin nephrotoxicity: the effect of dose, schedule, and hydration scheme. In: Prestayko AW, Crooke ST, Clarke SK, editors. Cisplatin: current status and new developments. Orlando: Academic Press, 1980: 485–94
  Google Scholar
• Willox JC, McAllister EJ, Sangster G, et al. Effects of magnesium supplementation in testicular cancer patients receiving cisplatin: a randomised trial. Br J Cancer 1986; 54: 19–23
  PubMed CAS Google Scholar
• Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988; 21: 163–7
  PubMed CAS Google Scholar
• Hargis JB, Anderson JR, Propert KJ, et al. Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a cancer and leukemia group B study. Cancer Chemother Pharmacol 1992; 39: 291–6
  Google Scholar
• Stewart DJ, Mikhael NZ, Nanji AA, et al. Renal and hepatic concentrations of platinum: relationships to cisplatin time, dose and nephrotoxicity. J Clin Oncol 1985; 3: 1251–6
  PubMed CAS Google Scholar
• Blumenreich MS, Woodcock TM, Jones M, et al. High-dose cisplatin in patients with advanced malignancies. Cancer 1985; 55: 1118–22
  PubMed CAS Google Scholar
• Nanji AA, Stewart DJ, Mikhael NZ. Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 1986; 17: 274–6
  PubMed CAS Google Scholar
• Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity correlation with plasma platinum concentrations. Am J Clin Oncol 1985; 8: 77–80
  PubMed CAS Google Scholar
• Campbell AB, Kaiman SM, Jacobs C. Plasma platinum levels: relationships to cisplatin dose and nephrotoxicity. Cancer Treat Rep 1983; 67: 169–72
  PubMed CAS Google Scholar
• Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. Acute renal failure after _cis_-dichlorodiammineplatinum(II) and gentamicin-cephalothin therapies. Cancer Treat Rep 1978; 62: 693–8
  PubMed CAS Google Scholar
• Salem PA, Jabboury KW, Khalil MF Severe nephrotoxicity: a probable complication of _cis_-dichlorodiammineplatinum(II) and cephalothin-gentamicin therapy. Oncology 1982; 39: 31–2
  PubMed CAS Google Scholar
• Calvert AH, Harland SJ, Newell DR, et al. Early clinical trials with _cis_-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9: 140–7
  PubMed CAS Google Scholar
• Mason MD, Nicholls J, Horwich A. The effect of carboplatin on renal function in patients with metastatic germ cell tumours. Br J Cancer 1991; 63: 630–3
  PubMed CAS Google Scholar
• Gore ME, Calvert AH, Smith IE. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase dose escalation. Eur J Cancer Clin Oncol 1987; 23: 1391–7
  PubMed CAS Google Scholar
• Shea TC, Flaherty M, Elias A, et al. A phase I and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651–61
  PubMed CAS Google Scholar
• Siddik ZH, Dible SE, Boxall FE, et al. Renal pharmacokinetics and toxicity of cisplatin and carboplatin in animals. In: McBrien DCH, Slater TF, editors. Biochemical mechanisms of platinum antitumour drugs. Oxford: IRL Press Ltd, 1986: 171–98
  Google Scholar
• Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203–8
  PubMed CAS Google Scholar
• Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramine: randomised trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 9: 905–9
  Google Scholar
• Cubeddu LX, Hoffman IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatin-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33: 691–7
  PubMed CAS Google Scholar
• Du Bios A, Meerpohl HG, Vach W, et al. Course, patterns, and risk factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 1992; 28: 450–7
  Google Scholar
• Harvey VJ, Evans BD, Mitchell PLR, et al. Reduction of carboplatin induced emesis by ondansetron. Br J Cancer 1991; 63: 942–4
  PubMed CAS Google Scholar
• Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agent. J Natl Cancer Inst 1991; 83: 613–20
  PubMed CAS Google Scholar
• Cubeddu LX, Hoffman IS, Fuenmayor NT, et al. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992; 66: 198–203
  PubMed CAS Google Scholar
• Cubeddu LX, Hoffman IS, Fuenmayor NT, et al. Efficacy of ondansetron (Gr 38032f) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810–6
  PubMed CAS Google Scholar
• Allan S, Smyth JF, Hay FG, et al. Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of _cis_-diamminedichloroplatinum. Cancer Res 1986; 46: 3569–73
  PubMed CAS Google Scholar
• Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide and dexamethasone. Cancer 1987; 60: 2816–22
  PubMed CAS Google Scholar
• Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytyptamine 3 (serotonin) antagonist ondansetron (Gr 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–21
  PubMed CAS Google Scholar
• Hainsworth J, Harvey W, Pendergrass K, et al. A single-blind comparison of intravenous ondansetron a selective antagonist with intravenous metoclopramide in the prevention of nausea and vomiting associated with high dose cisplatin chemotherapy. J Clin Oncol 1991; 9: 721–8
  PubMed CAS Google Scholar
• De Mulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared to high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–40
  PubMed Google Scholar
• Smith DB, Newlands ES, Rustin GJS, et al. Comparison of ondansetron and ondansetron and dexamethasone prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338: 487–90
  PubMed CAS Google Scholar
• Ozols RF, Corden BJ, Jacob J, et al. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984; 100: 19–24
  PubMed CAS Google Scholar
• Hamers FPT, Gispen WH, Neijt JP. Neurotoxicity side-effects of cisplatin. Eur J Cancer 1991; 27: 372–6
  CAS Google Scholar
• Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev 1989; 16: 195–211
  PubMed CAS Google Scholar
• Cavaletti G, Bogliun G, Marzorati L, et al. The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer. J Neurol 1991; 238: 371–4
  PubMed CAS Google Scholar
• Elderson A, Van Der Hoop GR, Haanstra W, et al. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci 1989; 93: 167–74
  PubMed CAS Google Scholar
• Lipton RB, Galer BS, Dutcher JP, et al. Quantitative sensory testing demonstrates that subclinical sensory neuropathy is prevalent in patients with cancer. Arch Neurol 1987; 44: 944–6
  PubMed CAS Google Scholar
• Van Der Hoop GR, Van Der Burg MEL, Ten Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66: 1697–702
  PubMed Google Scholar
• Thompson SW, Davies LE, Kornfeld M, et al. Cisplatin neurotoxicity: clinical, electrophysiolic, morphologic and toxicologic studies. Cancer 1984; 54: 1269–75
  PubMed CAS Google Scholar
• Cavaletti G, Tredici G, Marmiroli P, et al. Morphometric study of the sensory neuron and peripheral nerve changes by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 1992; 84: 364–71
  PubMed CAS Google Scholar
• Gregg RW, Molepa JM, Monpetit VJA, et al. Cisplatin neurotoxicity: the relationship between dosage, time and platinum concentration in neurological tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795–803
  PubMed CAS Google Scholar
• Terheggen PMAB, Van Der Hoop GR, Floot BGJ, et al. Cellular distribution of _cis_-diamminedichloroplatinum(II)-DNA binding in rat dorsal root spinal ganglia: effect of neuroprotecting peptide ORG 766. Toxicol Appl Pharmacol 1989; 99: 334–43
  PubMed CAS Google Scholar
• Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126–7
  PubMed CAS Google Scholar
• Mollman JE, Glover DJ, Hogan M, et al. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer 1988; 61: 2192–5
  PubMed CAS Google Scholar
• Legha SS, Dimery IW. High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 1985; 3: 1373–8
  PubMed CAS Google Scholar
• Gandara DR, Degregorio MW, Wold H, et al. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J Clin Oncol 1986; 4: 1787–93
  PubMed CAS Google Scholar
• Hamers FPT, Brakkee JH, Cavalletti E, et al. Reduced glutathi-one protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53: 544–9
  PubMed CAS Google Scholar
• Cascinu S, Cordelia L, Ferro ED, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomised double blind placebo-controlled trial. J Clin Oncol 1995; 1326-32
• Cavaletti G, Minoia C, Schieppati M, et al. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 1994; 29: 771–6
  PubMed CAS Google Scholar
• Abe R, Akiyoshi T, Tsuji H, et al. Protection of antiproliferative effect of _cis_-diamminedichloroplatinum(II) by sodium thiosulfate. Cancer Chemother Pharmacol 1986; 18: 98–100
  PubMed CAS Google Scholar
• Gandara DR, Natihas WA, Adelson MD, et al. Randomised placebo-controlled multicentre evaluation of diethyldithio-carbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995; 13: 490–6
  PubMed CAS Google Scholar
• Van Der Hoop GR, Vechet CJ, Van Der Burg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patient with ovarian cancer. N Engl J Med 1990; 322: 89–94
  PubMed Google Scholar
• Hovestadt A, Van Der Berg ME, Verbiest HB, et al. The course of neuropathy after cessation of cisplatin treatment combined with ORG2766 or placebo. J Neurol 1992; 239: 143–6
  PubMed CAS Google Scholar
• Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985; 12: 125–36
  PubMed Google Scholar
• Strauss M, Towfighi J, Lord S, et al. _Cis_-platinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope 1983; 93: 1554–9
  PubMed CAS Google Scholar
• Waters GS, Ahmad M, Katasarkas A, et al. Ototoxicity due to _cis_-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 1991; 12: 91–102
  PubMed CAS Google Scholar
• Aguilar-Markulis NV, Beckley S, Priore R, et al. Auditory toxicity effects of long-term _cis_-dichlorodiammineplatinum(II) therapy in genitourinary cancer patients. J Surg Oncol 1981; 16: 111–23
  PubMed CAS Google Scholar
• Schaefer SD, Post JD, Close LG, et al. Ototoxicity of low- and moderate-dose cisplatin. Cancer 1985; 56: 1934–9
  PubMed CAS Google Scholar
• Melmamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynaecology cancer patients. Cancer 1985; 55: 41–3
  Google Scholar
• Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990; 100: 724–34
  PubMed CAS Google Scholar
• Reddel RR, Kefford RF, Grant JM, et al. Ototoxicity in patients receiving cisplatin: importance of doses and method of drug administration. Cancer Treat Rep 1982; 66: 19–23
  PubMed CAS Google Scholar
• Wright CG, Schaefer SD. Inner ear histopathology in patients treated with _cis_-platinum. Laryngoscope 1982; 92: 1408–13
  PubMed CAS Google Scholar
• Stadnicki SW, Fleischman RW, Schaeppi U, et al. _Cis-_dichlorodiammineplatinum(II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep 1975; 59: 467–80
  PubMed Google Scholar
• Harpur ES. Ototoxicity: morphological and functional correlations between experimental and clinical studies. In: Ballantyne B, editor. Perspectives in basic and applied toxicology. London: Butterworth and Co, 1988: 42–69
  Google Scholar
• Kohn S, Fradis M, Podoshin L, et al. Toxic effects of cisplatin alone and in combination with gentamicin in stria vascularis of guinea pigs. Laryngoscope 1991; 101: 709–16
  PubMed CAS Google Scholar
• Fleischman RW, Stadnicki SW, Ethier MF, et al. Ototoxicity of _cis_-diamminedichloro platinum(II) in the guinea pig. Toxicol Appl Pharmacol 1975; 33: 320–32
  PubMed CAS Google Scholar
• Comis SD, Rhys-Evans PH, Osbourne MP, et al. Early morphological and chemical changes induced by cisplatin in the guinea pig organ of corti. J Laryngol Otol 1986; 100: 1373–83
  Google Scholar
• Nakai Y, Konishi K, Chang KC, et al. Ototoxicity of the anti-cancer drug cisplatin: an experimental study. Acta Otolaryngol 1982; 93: 227–32
  PubMed CAS Google Scholar
• Schweitzer VG, Rarey KE, Dolan DF, et al. Ototoxicity of cis-platin vs platinum analogs CBDCA (JM8) and CHIP (JM9). Otolaryngol Head Neck Surg 1986; 94: 458–69
  PubMed CAS Google Scholar
• McAlpine A, Johnson BM. The ototoxic mechanism of cis-platin. Hearing Res 1990; 47: 191–204
  CAS Google Scholar
• Piel IJ, Meyer D, Perlia CP, et al. Effects of _cis_-diammine-dichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep 1974; 58: 871–5
  PubMed CAS Google Scholar
• Boheim K, Bichler E. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol 1985; 242: 1–6
  PubMed CAS Google Scholar
• Meyer WH, Ayers D, Mchaney VA, et al. Ifosfamide and exacerbation of cisplatin-induced hearing loss. Lancet 1993; 341: 754–5
  PubMed CAS Google Scholar
• Kennedy ICS, Fitzharris BM, Colls BM, et al. Carboplatin is ototoxic. Cancer Chemother Pharmacol 1990; 26: 232–4
  PubMed CAS Google Scholar
• Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of _cis_-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979; 63: 1527–31
  Google Scholar
• Curt GA, Grygiel JJ, Corden BJ, et al. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylato-platinum (NSC241240). Cancer Res 1983; 43: 4470–3
  PubMed CAS Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56
  PubMed CAS Google Scholar
• Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin- 1α on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 756–61
  PubMed Google Scholar
• Beijen JH, Van Warmerdam LJC, Huizing MT, et al. Pharmacokinetics of carboplatin in dose finding and sequence study of the combination paclitaxel and carboplatin in non-small cell lung cancer: a European Cancer Centre Study [abstract]. International Symposium On Platinum And Other Metal Coordination Compounds In Cancer Therapy; 1995 Mar 1–4; Amsterdam, 7: 52
  Google Scholar
• Saunders MP, Denton CP, Os’Brien MER, et al. Hypersensitivity reactions to cisplatin and carboplatin: a report of six cases. Ann Oncol 1992; 3: 574–6
  PubMed CAS Google Scholar
• Hendrick AM, Simmons D, Cantwell BMJ. Allergic reactions to carboplatin. Ann Oncol 1992; 3: 239–40
  PubMed CAS Google Scholar
• Hunter D, Milton R, Perry KMA. Asthma caused by complex salts of platinum. Br J Indust Med 1945; 30: 27–30
  Google Scholar
• Calvert AH, Judson I, Van Der Vijgh WJF. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surveys 1993; 17: 189–217
  PubMed CAS Google Scholar
• Bajorin DF, Bosl GJ, Alcock NW, et al. Pharmacokinetics of _cis_-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res 1986; 46: 5969–72
  PubMed CAS Google Scholar
• Corden BJ, Fine RL, Ozols RF, et al. Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmacol 1985; 14: 38–41
  PubMed CAS Google Scholar
• Belt RJ, Himmelstein KJ, Patton TF, et al. Pharmacokinetics of non-protein-bound species following administration of _cis-_diamminedichloroplatinum(II). Cancer Treat Rep 1979; 63: 1515–21
  PubMed CAS Google Scholar
• Van Der Vijgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21: 242–61
  PubMed Google Scholar
• Harland SJ, Newell DR, Siddik ZH, et al. Pharmacokinetics of _cis_-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984; 44: 1693–7
  PubMed CAS Google Scholar
• Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of _cis_-diammine(1,1-cyclobutanedi-carboxylato)platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432–8
  PubMed CAS Google Scholar
• Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the _cis-_diamminedichloroplatinum(II) analogue diamminecyclobu-tanedicarboxylatoplatinum. Cancer Res 1985; 45: 6502–6
  PubMed CAS Google Scholar
• Newell DR, Pearson ADJ, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosage formula. J Clin Oncol 1993; 11: 2314–23
  PubMed CAS Google Scholar
• Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573–80
  PubMed CAS Google Scholar
• Giandomenico CM, Abrams MJ, Murrer BA, et al. Synthesis and reactions of a new class of orally active Pt(IV) antitumour complexes. In: Howell SB, editor. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991: 93–100
  Google Scholar
• Van Hennik MB, Van der Vijgh WJF, Klein I, et al. Human pharmacokinetics of carboplatin after oral administration. Cancer Chemother Pharmacol 1989; 23: 126–7
  PubMed Google Scholar
• Siddik ZH, Boxall FE, Goodard PM, et al. Antitumour, pharmacokinetic and toxicity studies with orally administered cis-platin, CBDCA and CHIP [abstract 1462]. Proc Am Assoc Cancer Res. 1984; 25: 369
  Google Scholar
• McKeage MJ, Morgan SE, Boxall FE, et al. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br J Cancer 1993; 67: 996–1000
  PubMed CAS Google Scholar
• McKeage MJ, Boxall F, Jones M, et al. Lack of neurotoxicity of oral bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 1994; 54: 629–31
  PubMed CAS Google Scholar
• McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacological study of an oral platinum complex (JM216): dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol. In Press
• McKeage MJ, Morgan SE, Boxall FE, et al. Preclinical toxicology and tissue distribution of novel oral antitumour platinum complexes: ammine/amine platinum (IV) dicarboxylates. Cancer Chemother Pharmacol 1994; 33: 497–503
  PubMed CAS Google Scholar
• Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumour evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993; 53: 2581–6
  PubMed CAS Google Scholar
• McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an orally administered platinum (Pt) complex (JM216) using a daily x 5 administration schedule [abstract]. Proc Am Soc Clin Oncol 1994; 13: 337a
  Google Scholar
• McKeage MJ, Kelland LR, Boxall FE, et al. Schedule dependency of orally administered bis-acetato-ammine-dichlorocyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res 1994; 54: 4118–22
  Google Scholar
• Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with _cis_-platinum and carboplatinum. Biomed Pharmacother. 1989; 43: 237–50
  PubMed CAS Google Scholar
• Sekiguchi M, Eriguchi M, Shiroko Y, et al. Chemosensitivity screening in vitro of various cultured human cancer cell lines to a new platinum complex L-OHP; oxalato(trans-1-1,2-diaminocyclohexane)platinum(II). Ann Oncol 1992; 2: 194a
  Google Scholar
• Boughattas NA, Levi F, Fournier C, et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res 1989; 49: 3362–8
  PubMed CAS Google Scholar
• Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303
  PubMed CAS Google Scholar
• Levi F, Misset J, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using a ambulatory multichannel programmable pump: high effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893–900
  PubMed CAS Google Scholar
• Schilder RJ, La Creta FP, Perez RP, et al. Phase 1 and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and 8 schedule. Cancer Res 1994; 54: 709–17
  PubMed CAS Google Scholar